PURPOSE: Bevacizumab has been shown to increase progression free and overall survival in patients with metastatic colorectal cancer. Neoadjuvant bevacizumab is commonly used in patients undergoing liver resection. Our purpose was to evaluate whether bevacizumab is associated with increased rate of perioperative complications in patients undergoing hepatic resection for colorectal liver metastases (CRLM). METHODS: Retrospective analysis of patients undergoing hepatic resection for CRLM who received chemotherapy and bevacizumab (group 1, n = 134), or chemotherapy alone (group 2, n = 57). We compared demographics, surgical characteristics, and perioperative course. RESULTS: Perioperative complications developed in 35 % of patients in group 1, and 47 % in group 2 (p = 0.11). Of those complications, 15 (11.2 %) in group 1, and 5 (8.8 %) in group 2 were considered major (p = 0.617). Four patients, all of whom received preoperative bevacizumab, developed enteric leaks following combined liver and bowel resection. The rate of anastomotic leak in group 1 was 10 %, compared with 0 in group 2, p = 0.56. CONCLUSION: Neoadjuvant chemotherapy along with bevacizumab was not associated with an increased risk of postoperative complications after hepatic resection. Possible association of increased morbidity with simultaneous bowel and liver resections following bevacizumab administration was found and we recommend avoiding such treatment combination.
PURPOSE:Bevacizumab has been shown to increase progression free and overall survival in patients with metastatic colorectal cancer. Neoadjuvant bevacizumab is commonly used in patients undergoing liver resection. Our purpose was to evaluate whether bevacizumab is associated with increased rate of perioperative complications in patients undergoing hepatic resection for colorectal liver metastases (CRLM). METHODS: Retrospective analysis of patients undergoing hepatic resection for CRLM who received chemotherapy and bevacizumab (group 1, n = 134), or chemotherapy alone (group 2, n = 57). We compared demographics, surgical characteristics, and perioperative course. RESULTS: Perioperative complications developed in 35 % of patients in group 1, and 47 % in group 2 (p = 0.11). Of those complications, 15 (11.2 %) in group 1, and 5 (8.8 %) in group 2 were considered major (p = 0.617). Four patients, all of whom received preoperative bevacizumab, developed enteric leaks following combined liver and bowel resection. The rate of anastomotic leak in group 1 was 10 %, compared with 0 in group 2, p = 0.56. CONCLUSION: Neoadjuvant chemotherapy along with bevacizumab was not associated with an increased risk of postoperative complications after hepatic resection. Possible association of increased morbidity with simultaneous bowel and liver resections following bevacizumab administration was found and we recommend avoiding such treatment combination.
Authors: Thomas Aloia; Mylène Sebagh; Marylène Plasse; Vincent Karam; Francis Lévi; Sylvie Giacchetti; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: Susan B Kesmodel; Lee M Ellis; E Lin; George J Chang; Eddie K Abdalla; Scott Kopetz; Jean-Nicolas Vauthey; Miguel A Rodriguez-Bigas; Steven A Curley; Barry W Feig Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz Journal: J Natl Cancer Inst Date: 2007-08-08 Impact factor: 13.506
Authors: Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič Journal: Eur J Clin Pharmacol Date: 2019-02-05 Impact factor: 2.953
Authors: Andreas M Volk; Johannes Fritzmann; Christoph Reissfelder; Georg F Weber; Jürgen Weitz; Nuh N Rahbari Journal: BMC Cancer Date: 2016-02-10 Impact factor: 4.430